<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418714/" ref="ordinalpos=2104&amp;ncbi_uid=5178920&amp;link_uid=PMC3418714" image-link="/pmc/articles/PMC3418714/figure/F2/" class="imagepopup">Figure 2.  From: The B-cell receptor <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span> as a therapeutic target in CLL. </a></div><br /><div class="p4l_captionBody"><b>Integrin signaling in CLL.</b> (A) Inside-out integrin signaling. Signaling through the BCR, dependent on Btk and PLC-Î³2, activates the cytoplasmic domain of the integrin, causing a conformational change to the open, active form. This form has high affinity for ligand binding and induces cell migration and adhesion. (B) Outside-in integrin signaling. Ligand binding to an integrin induces signals that can lead to growth, differentiation, survival, or apoptosis.</div></div>